TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 23278124

Group type: EXPERIMENTAL
Intervention: Silymarin (Legalon®) with desferrioxamine
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo with desferrioxamine
Number of subjects: 97
Study: 22338362

Group type: EXPERIMENTAL
Intervention: Acustimulation
Number of subjects: 25

Group type: COMPARATOR
Intervention: Acupressure
Number of subjects: 25

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 25
Study: 19477351

Group type: COMPARATOR
Intervention: Ramipril 15 mg/day
Number of subjects: 1425

Group type: EXPERIMENTAL
Intervention: Rosiglitazone 8 mg/day
Number of subjects: 1425

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 1425
Study: 16902840

Group type: EXPERIMENTAL
Intervention: MCT with wheeze detection (MCT("Wheeze"))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MCT with FEV1 decline (MCT("FEV1"))
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: MCT with either FEV1 decline or wheeze detection (MCT("FEV1Wheeze"))
Number of subjects: 80
Study: 15126742

Group type: EXPERIMENTAL
Intervention: 1% aqueous NCT solution (1 mL)
Number of subjects: 50

Group type: COMPARATOR
Intervention: Otosporin (1 mL)
Number of subjects: 50
Study: 11405326

Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution after adjusting for serum hormone levels
Number of subjects: 282

Group type: EXPERIMENTAL
Intervention: Upper fourth of the BMD distribution after adjusting for body mass index and years since menopause
Number of subjects: 282
Study: 9322475

Group type: COMPARATOR
Intervention: CO2 pneumoperitoneum (IAP 12‐13 mm Hg) (control)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Gasless abdominal wall lift method (retractor)
Number of subjects: 30
Study: 8461682

Group type: EXPERIMENTAL
Intervention: Vitamin A supplementation
Number of subjects: 12
Study: 3963318

Group type: EXPERIMENTAL
Intervention: Oral flunitrazepam
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Oral pentobarbital
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: Oral NaCl solution
Number of subjects: 600

Group type: COMPARATOR
Intervention: Intramuscular pethidine
Number of subjects: 600

Group type: COMPARATOR
Intervention: Intramuscular droperidol/fentanyl
Number of subjects: 600

Group type: COMPARATOR
Intervention: Intramuscular NaCl solution
Number of subjects: 600
Study: 29511819

Group type: EXPERIMENTAL
Intervention: MSCs (n=9)
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: MSCs+PRP (n=9)
Number of subjects: 18

Group type: COMPARATOR
Intervention: MSCs and MSCs+PRP
Number of subjects: 18
Study: 25914349

Group type: EXPERIMENTAL
Intervention: 10 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 20 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: 40 intravesical BoNT‐A injections (100 U in 10 mL)
Number of subjects: 67

Group type: EXPERIMENTAL
Intervention: All groups (10, 20, 40 injections)
Number of subjects: 67
Study: 25385363

Group type: EXPERIMENTAL
Intervention: Phenobarbital
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Levetiracetam
Number of subjects: 99

Group type: EXPERIMENTAL
Intervention: Antiepileptic drugs (AEDs)
Number of subjects: 99

Group type: COMPARATOR
Intervention: Control (cerebral post-stroke injury without seizures)
Number of subjects: 99
Study: 22085338

Group type: EXPERIMENTAL
Intervention: High-dosage bevacizumab (15 mg/kg)
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: Low-dosage bevacizumab (7.5 mg/kg)
Number of subjects: 2210

Group type: EXPERIMENTAL
Intervention: Bevacizumab (both dosages)
Number of subjects: 2210

Group type: COMPARATOR
Intervention: Chemotherapy alone
Number of subjects: 2210
Study: 20370912

Group type: EXPERIMENTAL
Intervention: Febuxostat 40 mg
Number of subjects: 2269

Group type: EXPERIMENTAL
Intervention: Febuxostat 80 mg
Number of subjects: 2269

Group type: COMPARATOR
Intervention: Allopurinol 300 mg (200 mg in moderate renal impairment)
Number of subjects: 2269
Study: 18371100

Group type: EXPERIMENTAL
Intervention: Bar-anchored overdentures
Number of subjects: 328

Group type: COMPARATOR
Intervention: Telescopic crown-retained overdentures
Number of subjects: 328
Study: 15855014

Group type: EXPERIMENTAL
Intervention: HPV-16 L1 VLP vaccine
Number of subjects: 24

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 24
Study: 12441935

Group type: EXPERIMENTAL
Intervention: Mitoxantrone plus prednisone
Number of subjects: 120

Group type: COMPARATOR
Intervention: Prednisone alone
Number of subjects: 120
Study: 10616257

Group type: EXPERIMENTAL
Intervention: Individual administration of HGSHS:A, TAS, DES, PCI
Number of subjects: 80

Group type: COMPARATOR
Intervention: Group administration of HGSHS:A, TAS, DES, PCI
Number of subjects: 80
Study: 7575761

Group type: EXPERIMENTAL
Intervention: Test preparation of cyclosporine
Number of subjects: 10

Group type: COMPARATOR
Intervention: Control preparation of cyclosporine
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Non-specific method for measuring pharmacokinetic parameters
Number of subjects: 10
Study: 2040241

Group type: EXPERIMENTAL
Intervention: 5% glucose
Number of subjects: 70

Group type: COMPARATOR
Intervention: 0.9% saline
Number of subjects: 70

Group type: COMPARATOR
Intervention: No intravenous fluids
Number of subjects: 70
Study: 7431199

Group type: EXPERIMENTAL
Intervention: Congruent subjects (Fl-I and FD-I)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: All subjects (Fl-I, FD-I, Fl-E, FD-E)
Number of subjects: 80
Study: 31765520

Group type: EXPERIMENTAL
Intervention: Standard electrode position
Number of subjects: 30

Group type: COMPARATOR
Intervention: Alternative electrode positions (lateral, superior, medial, inferior, dorsal)
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Medial and inferior electrode placement
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: Lateral electrode placement
Number of subjects: 30
Study: 31870417

Group type: EXPERIMENTAL
Intervention: General Anesthesia (GA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA)
Number of subjects: 70

Group type: COMPARATOR
Intervention: Spinal Anesthesia (SA) with sedation
Number of subjects: 70
Study: 27882470

Group type: EXPERIMENTAL
Intervention: Bipolar TURBT
Number of subjects: 160

Group type: COMPARATOR
Intervention: Monopolar TURBT
Number of subjects: 160
Study: 25528104

Group type: EXPERIMENTAL
Intervention: Acupuncture treatment (AT) group
Number of subjects: 24

Group type: COMPARATOR
Intervention: Acupuncture stimulation (AS) group
Number of subjects: 24
Study: 23371492

Group type: COMPARATOR
Intervention: 20 mg cortisol
Number of subjects: 67

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 67
Study: 21447750

Group type: EXPERIMENTAL
Intervention: Sex group (received messages related to safer sex)
Number of subjects: 7606

Group type: COMPARATOR
Intervention: Sun group (received messages related to sun safety)
Number of subjects: 7606

Group type: EXPERIMENTAL
Intervention: Sex group
Number of subjects: 7606
Study: 19735771

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) combined with a defined therapy program
Number of subjects: 21

Group type: COMPARATOR
Intervention: Therapy alone
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Botulinum toxin type A (BTX‐A) combined with therapy
Number of subjects: 21

Group type: EXPERIMENTAL
Intervention: Both groups (BTX‐A and therapy alone)
Number of subjects: 21
Study: 18067007

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin (81 mg) with thalidomide/dexamethasone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with thalidomide/dexamethasone
Number of subjects: 72

Group type: EXPERIMENTAL
Intervention: Low-dose aspirin with lenalidomide-containing regimen (clarithromycin, lenalidomide, dexamethasone)
Number of subjects: 72

Group type: COMPARATOR
Intervention: Dexamethasone alone (without aspirin)
Number of subjects: 72
Study: 15519009

Group type: EXPERIMENTAL
Intervention: Bivalirudin with provisional GP IIb/IIIa inhibition
Number of subjects: 4651

Group type: COMPARATOR
Intervention: Heparin + routine GP IIb/IIIa inhibition
Number of subjects: 4651
Study: 11304812

Group type: EXPERIMENTAL
Intervention: Intraocular lens (IOL)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Contact lens (CL)
Number of subjects: 25
Study: 9559764

Group type: EXPERIMENTAL
Intervention: Tidal volume or inspired PCO2 modification to alter PaCO2 levels
Number of subjects: 36

Group type: EXPERIMENTAL
Intervention: Preserved CBF response to CO2
Number of subjects: 36

Group type: COMPARATOR
Intervention: Transcranial Doppler ultrasonography
Number of subjects: 36
Study: 8180514

Group type: EXPERIMENTAL
Intervention: Percutaneous transluminal coronary angioplasty (PTCA)
Number of subjects: 0
Study: 2644337

Group type: EXPERIMENTAL
Intervention: Fluoxetine 60-80 mg/day
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 14
Study: 4753715

Group type: EXPERIMENTAL
Intervention: High Density Rolling Stock under different densities and environmental constraints
Number of subjects: 0
Study: 30375910

Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin plus doxorubicin, vinblastine, and dacarbazine (A + AVD)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Doxorubicin, bleomycin, vinblastine, and dacarbazine (ABVD)
Number of subjects: 0
Study: 28263650

Group type: EXPERIMENTAL
Intervention: Supportive-expressive (SE) psychodynamic treatment
Number of subjects: 0
Study: 25212601

Group type: EXPERIMENTAL
Intervention: 3D conformal radiation therapy (3D‐CRT, 70 Gy/35 fractions)
Number of subjects: 129

Group type: COMPARATOR
Intervention: Intensity‐modulated radiation therapy (IMRT, 76 Gy/38 fractions)
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: APC for Grade 2 or 3 rectal bleeding
Number of subjects: 129

Group type: EXPERIMENTAL
Intervention: V65 ≥ 17%
Number of subjects: 129
Study: 23444424

Group type: EXPERIMENTAL
Intervention: Telehealth
Number of subjects: 3230

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 3230
Study: 21443965

Group type: EXPERIMENTAL
Intervention: ACWY-TT + MMRV
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: ACWY-TT
Number of subjects: 1000

Group type: EXPERIMENTAL
Intervention: MMRV
Number of subjects: 1000

Group type: COMPARATOR
Intervention: MenC-CRM(197)
Number of subjects: 1000
Study: 18193919

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Ibuprofen (400 mg)
Number of subjects: 10

Group type: EXPERIMENTAL
Intervention: Aspirin (325 mg) and Ibuprofen (400 mg) concomitantly
Number of subjects: 10
Study: 19462544

Group type: EXPERIMENTAL
Intervention: Walking program (aerobic exercise)
Number of subjects: 25

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 25
Study: 12540598

Group type: EXPERIMENTAL
Intervention: Rosiglitazone (4 mg b.i.d.)
Number of subjects: 41

Group type: EXPERIMENTAL
Intervention: Metformin (1 g b.i.d.)
Number of subjects: 41
Study: 10757453

Group type: EXPERIMENTAL
Intervention: High-fat meal
Number of subjects: 18

Group type: COMPARATOR
Intervention: Low-fat meal
Number of subjects: 18
Study: 9013382

Group type: EXPERIMENTAL
Intervention: Dexibuprofen (Seractil: S(+)‐ibuprofen)
Number of subjects: 0
Study: 1354274

Group type: EXPERIMENTAL
Intervention: Aspirin (75 mg daily)
Number of subjects: 740

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 740
Study: 6355055

Group type: EXPERIMENTAL
Intervention: 5% acyclovir cream
Number of subjects: 30
Study: 31701238

Group type: EXPERIMENTAL
Intervention: IG-MA (remobilization strategy in a memory clinic)
Number of subjects: 81

Group type: COMPARATOR
Intervention: KG1-AGR (standard remobilization unit)
Number of subjects: 81

Group type: COMPARATOR
Intervention: KG2-PWH (care homes)
Number of subjects: 81
Study: 30672128

Group type: EXPERIMENTAL
Intervention: mirogabalin 30 mg/day
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: mirogabalin 20 mg/day
Number of subjects: 834

Group type: EXPERIMENTAL
Intervention: mirogabalin 15 mg/day
Number of subjects: 834

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 834
Study: 26260325

Group type: EXPERIMENTAL
Intervention: Telehealth (TH) intervention
Number of subjects: 447

Group type: COMPARATOR
Intervention: Control group (not specified)
Number of subjects: 447
Study: 24662235

Group type: EXPERIMENTAL
Intervention: Linear Periodization (LP)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Daily Undulating Periodization (DUP)
Number of subjects: 13
Study: 24461313

Group type: EXPERIMENTAL
Intervention: Krill oil (0.5, 1, 2, or 4 g/day)
Number of subjects: 300

Group type: COMPARATOR
Intervention: Placebo (olive oil)
Number of subjects: 300
Study: 22012469

Group type: EXPERIMENTAL
Intervention: 0.8% hyaluronan gel
Number of subjects: 14

Group type: COMPARATOR
Intervention: Placebo gel
Number of subjects: 14
Study: 19302393

Group type: EXPERIMENTAL
Intervention: New cross-linked collagen membrane (VN)
Number of subjects: 54

Group type: COMPARATOR
Intervention: Native collagen membrane (BG)
Number of subjects: 54
Study: 16914226

Group type: EXPERIMENTAL
Intervention: Flavor enhancement (700 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Monosodium glutamate (MSG) (300 mg)
Number of subjects: 83

Group type: EXPERIMENTAL
Intervention: Flavor plus MSG
Number of subjects: 83

Group type: COMPARATOR
Intervention: Control group
Number of subjects: 83
Study: 15573070

Group type: EXPERIMENTAL
Intervention: Cold blood cardioplegia (group B)
Number of subjects: 1440

Group type: COMPARATOR
Intervention: Cold crystalloid cardioplegia (group C)
Number of subjects: 1440
Study: 11894974

Group type: EXPERIMENTAL
Intervention: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg per 1.73 m2)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High dose ACTH [1‐24] (250 microg, 60-minute HDT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: 8-h infusion test (250 microg ACTH [1‐24] at a constant rate over 8 h)
Number of subjects: 42

Group type: COMPARATOR
Intervention: Insulin hypoglycaemia test (IHT)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: Low dose ACTH [1‐24] (0.1 microg, 0.5 microg, 1.0 microg)
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: High dose ACTH [1‐24] (HDT)
Number of subjects: 42
Study: 9452545

Group type: COMPARATOR
Intervention: In-office 35% carbamide peroxide bleaching product in 2 visits of 15 minutes each
Number of subjects: 20

Group type: EXPERIMENTAL
Intervention: Combination at-home and in-office system with a 15% carbamide peroxide at-home bleaching agent
Number of subjects: 20
Study: 8198938

Group type: EXPERIMENTAL
Intervention: Trimetazidine (20 mg three times daily)
Number of subjects: 149

Group type: COMPARATOR
Intervention: Propranolol (40 mg three times daily)
Number of subjects: 149

Group type: EXPERIMENTAL
Intervention: Trimetazidine
Number of subjects: 149

Group type: COMPARATOR
Intervention: Propranolol
Number of subjects: 149
Study: 3141537

Group type: EXPERIMENTAL
Intervention: Aspirin (topical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Indomethacin (topical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Piroxicam (topical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: N-hydroxy-arachidonamide (AH) (topical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenidone (topical)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Phenidone with ionomycin (topical)
Number of subjects: 0
Study: 28534247

Group type: EXPERIMENTAL
Intervention: Adolescent motivation for PA
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Authoritative parenting
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Tangible support
Number of subjects: 148

Group type: EXPERIMENTAL
Intervention: Emotional support
Number of subjects: 148
Study: 26746631

Group type: EXPERIMENTAL
Intervention: Cardiac CT
Number of subjects: 350

Group type: COMPARATOR
Intervention: Functional testing
Number of subjects: 350
Study: 25470086

Group type: EXPERIMENTAL
Intervention: Long-acting injectable (LAI) antipsychotics
Number of subjects: 0

Group type: COMPARATOR
Intervention: Oral antipsychotic regimens
Number of subjects: 0
Study: 23841729

Group type: EXPERIMENTAL
Intervention: ATRA plus arsenic trioxide
Number of subjects: 156

Group type: COMPARATOR
Intervention: ATRA plus chemotherapy
Number of subjects: 156
Study: 20444251

Group type: EXPERIMENTAL
Intervention: EQ-5D
Number of subjects: 389

Group type: EXPERIMENTAL
Intervention: EQ-5D index
Number of subjects: 389

Group type: COMPARATOR
Intervention: EQ VAS, EQ-5D index
Number of subjects: 389
Study: 17173719

Group type: EXPERIMENTAL
Intervention: Tailored outreach intervention plus usual care
Number of subjects: 348

Group type: COMPARATOR
Intervention: Usual care alone
Number of subjects: 348
Study: 15333602

Group type: EXPERIMENTAL
Intervention: Advanced provision of three courses of emergency contraception (EC)
Number of subjects: 1030

Group type: COMPARATOR
Intervention: Control group obtaining each course of EC from clinic
Number of subjects: 1030

Group type: EXPERIMENTAL
Intervention: Both groups (intervention and control)
Number of subjects: 1030
Study: 11407439

Group type: EXPERIMENTAL
Intervention: Bromperidol 6‐18 mg/day for 3 weeks
Number of subjects: 30
Study: 9510490

Group type: EXPERIMENTAL
Intervention: Plasma testosterone (TTT) levels in patients with CAD (252+/‐125 ng/ml)
Number of subjects: 201

Group type: EXPERIMENTAL
Intervention: Plasma testosterone (TTT) level
Number of subjects: 201
Study: 7812682

Group type: EXPERIMENTAL
Intervention: RP-59227 (240 mg oral dose)
Number of subjects: 8

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 8

Group type: EXPERIMENTAL
Intervention: RP-59227
Number of subjects: 8
Study: 3042485

Group type: EXPERIMENTAL
Intervention: Acarbose
Number of subjects: 16

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 16
Study: 29289496

Group type: EXPERIMENTAL
Intervention: Sit-stand workstation with 4 months of sitting-specific motivational support
Number of subjects: 36

Group type: COMPARATOR
Intervention: Ergonomic focused motivational support
Number of subjects: 36
Study: 26808666

Group type: EXPERIMENTAL
Intervention: Calcium supplementation
Number of subjects: 210

Group type: EXPERIMENTAL
Intervention: Oral contraceptive pills containing drospirenone
Number of subjects: 210

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 210
Study: 25111196

Group type: EXPERIMENTAL
Intervention: Nonsterile gloves after hand hygiene (group A)
Number of subjects: 120

Group type: COMPARATOR
Intervention: Hand hygiene alone (group B)
Number of subjects: 120
Study: 24330707

Group type: EXPERIMENTAL
Intervention: Frovatriptan
Number of subjects: 129

Group type: COMPARATOR
Intervention: Rizatriptan
Number of subjects: 129
Study: 20666271

Group type: EXPERIMENTAL
Intervention: ICD (n = 507)
Number of subjects: 82

Group type: COMPARATOR
Intervention: AAD (n = 509)
Number of subjects: 82
Study: 17947349

Group type: EXPERIMENTAL
Intervention: 3D‐BMDA
Number of subjects: 38

Group type: COMPARATOR
Intervention: MBIDS
Number of subjects: 38
Study: 16634384

Group type: EXPERIMENTAL
Intervention: Ethyl chloride spray
Number of subjects: 77

Group type: COMPARATOR
Intervention: Ametop cream
Number of subjects: 77
Study: 14978593

Group type: EXPERIMENTAL
Intervention: Metoprolol
Number of subjects: 200

Group type: COMPARATOR
Intervention: Control (no metoprolol)
Number of subjects: 200
Study: 11581049

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement using ultrasonic pachymeters
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement in African American subjects
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Central corneal thickness measurement in white subjects
Number of subjects: 1301

Group type: EXPERIMENTAL
Intervention: Factors associated with greater mean central corneal thickness
Number of subjects: 1301
Study: 9732910

Group type: EXPERIMENTAL
Intervention: Niacin supplementation
Number of subjects: 0

Group type: COMPARATOR
Intervention: Warfarin
Number of subjects: 0

Group type: COMPARATOR
Intervention: Antioxidants
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 8151317

Group type: EXPERIMENTAL
Intervention: Multiagent chemotherapy and cranial irradiation
Number of subjects: 220

Group type: EXPERIMENTAL
Intervention: High doses of methotrexate and cytarabine (ara‐c)
Number of subjects: 220

Group type: COMPARATOR
Intervention: Cranial irradiation (18 Gy for SR, 24 Gy for HR and VHR)
Number of subjects: 220
Study: 3047215

Group type: EXPERIMENTAL
Intervention: prednisolone 21‐phosphate 30 mg (PP)
Number of subjects: 18

Group type: COMPARATOR
Intervention: beclomethasone dipropionate 1 mg (BDP)
Number of subjects: 18
Study: 30362889

Group type: EXPERIMENTAL
Intervention: Eccentric exercise
Number of subjects: 50
Study: 26925897

Group type: EXPERIMENTAL
Intervention: Ergonomics educational intervention based on Transtheoretical Model (TTM) variables, conducted over four weeks.
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control group (no specific intervention mentioned).
Number of subjects: 82
Study: 23426902

Group type: EXPERIMENTAL
Intervention: Extended-release carbidopa-levodopa (IPX066)
Number of subjects: 27

Group type: COMPARATOR
Intervention: Immediate-release carbidopa-levodopa (IR CD-LD)
Number of subjects: 27

Group type: EXPERIMENTAL
Intervention: Both formulations (IPX066 and IR CD-LD)
Number of subjects: 27
Study: 22101764

Group type: EXPERIMENTAL
Intervention: Dexpramipexole (50, 150 or 300 mg d(‐1))
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Dexpramipexole (50 mg d(‐1) or 300 mg d(‐1))
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 19225038

Group type: EXPERIMENTAL
Intervention: Fixed combination perindopril-indapamide
Number of subjects: 11140

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 11140
Study: 16988008

Group type: EXPERIMENTAL
Intervention: Ebola virus DNA vaccine (2 mg, 4 mg, or 8 mg)
Number of subjects: 26

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 26
Study: 14682408

Group type: EXPERIMENTAL
Intervention: BB genotype of eNOS gene
Number of subjects: 42

Group type: EXPERIMENTAL
Intervention: NonBB genotypes of eNOS gene
Number of subjects: 42

Group type: COMPARATOR
Intervention: ACE gene polymorphism
Number of subjects: 42
Study: 10790932

Group type: EXPERIMENTAL
Intervention: Community-directed 'healthy lifestyle' program
Number of subjects: 49

Group type: COMPARATOR
Intervention: Comparison group
Number of subjects: 49
Study: 9310876

Group type: EXPERIMENTAL
Intervention: EMDOGAIN treatment as an adjunct to modified widman flap (MWF) surgery
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment with MWF surgery
Number of subjects: 33

Group type: EXPERIMENTAL
Intervention: EMDOGAIN treatment
Number of subjects: 33

Group type: COMPARATOR
Intervention: Placebo treatment
Number of subjects: 33